BiomX (PHGE) Cash & Equivalents (2018 - 2026)

BiomX has reported Cash & Equivalents for 9 years, with the latest figure at $493000.0 in Q1 2026.

• Quarterly Cash & Equivalents fell 97.55% year-over-year to $493000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $493000.0 (down 97.55% YoY) and the FY2025 annual result came in at $3.1 million, down 81.7% from the prior year.
• Cash & Equivalents slipped to $493000.0 in Q1 2026 per PHGE's latest filing, from $3.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $31.6 million in Q2 2024 and troughed at $493000.0 in Q1 2026.
• A 5-year average of $19.7 million and a median of $22.4 million in 2023 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 13.07% in 2024, down 98.27% in 2024.
• Over 5 years, Cash & Equivalents stood at $31.3 million in 2022, then sank by 52.42% to $14.9 million in 2023, then grew by 13.07% to $16.9 million in 2024, then slumped by 81.7% to $3.1 million in 2025, then plunged by 84.01% to $493000.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $493000.0, $3.1 million, and $6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.